Jazz Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 11 trials

TrialDrugs studiedStatusPrimary completion
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575Cisplatin, Durvalumab, Gemcitabine, Pembrolizumab and 1 moreRecruiting2028-12-01Estimated
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)NCT05580562Dordaviprone (ONC201)Recruiting2028-06Estimated
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429Capecitabine, Eribulin, Gemcitabine, Trastuzumab and 2 moreRecruiting2028-04-28Estimated
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHNCT07625280XywavRecruiting2027-12-23Estimated
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT051521475-Fluorouracil, Capecitabine, Cisplatin, Oxaliplatin and 3 moreActive not recruiting2026-07-15Actual
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04657666NabiximolsCompleted2022-05-04Actual
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresNCT04485104GWP42003-PTerminated2025-01-28Actual
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresNCT05288283GWP42003-PTerminated2023-09-28Actual
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisNCT04203498NabiximolsTerminated2023-02-10Actual
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04984278NabiximolsTerminated2022-11-11Actual
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid LeukemiaNCT04571645Control, DociparstatTerminated2022-05-16Actual

Phase 2 / 3 1 trial

Phase 2 18 trials

TrialDrugs studiedStatusPrimary completion
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCNCT07459634Durvalumab, LurbinectedinRecruiting2029-08-04Estimated
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaNCT07282587ONC206, ONC206: Dose 1, ONC206: Dose 2Recruiting2028-12-15Estimated
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaNCT07533942JZP3507Recruiting2028-10-25Estimated
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Carboplatin, Docetaxel, Paclitaxel, Pertuzumab and 2 moreRecruiting2027-12-29Estimated
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845ZanidatamabRecruiting2026-12-31Estimated
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNCT03929666Bevacizumab, Capecitabine, Cisplatin, Fluorouracil and 4 moreCompleted2025-08-30Actual
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's DiseaseNCT05642442SuvecaltamideCompleted2024-10-23Actual
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)NCT05122650JZP385Completed2024-05-30Actual
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum DisorderNCT04745026GWP42003-PCompleted2023-12-21Actual
A Study of JZP150 in Adults With Posttraumatic Stress DisorderNCT05178316JZP150Completed2023-12-05Actual
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract CancersNCT04466891ZW25 (Zanidatamab)Completed2023-07-28Actual
Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantNCT04224272Fulvestrant, Palbociclib, ZW25 (Zanidatamab)Completed2023-04-28Actual
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaNCT02873338Cytarabine, Dociparstat sodium, IdarubicinCompleted2019-06Actual
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsNCT05126433LurbinectedinTerminated2023-12-20Actual
Oral ONC201 in Adult Recurrent GlioblastomaNCT02525692Dordaviprone (ONC201)Terminated2023-04-17Actual
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerNCT03485729Dordaviprone (ONC201)Terminated2023-01-19Actual
ONC201 in Adults With Recurrent H3 K27M-mutant GliomaNCT03295396Dordaviprone (ONC201)Terminated2022-12-31Actual
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456GWP42003-PTerminated2022-03-16Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of dose-limiting toxicities (DLTs) (Part 1) Description: Number of participants who experienced a DLT. DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen. Time frame: Up to 6 weeks Measure: Incidence of adverse events (Part 1) Description: Number of participants who experienced an adverse event Time frame: Up to 11 months Measure: Incidence of lab abnormalities (Part 1) Description: Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology and chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Time frame: Up to 11 months Measure: Objective response rate (ORR) (Part 2) Description: Number of participants who achieved a best response of either complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Time frame: Up to 10 months. After: Measure: Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1) Description: DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen. Time frame: Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens) Measure: Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2) Description: AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0). Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months Measure: Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2) Description: Grades of laboratory abnormalities were defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months Measure: Confirmed Objective Response Rate (ORR) (Parts 1 and 2) Description: Number of participants who achieved a confirmed best response of either complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Time frame: From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Overall survival (OS) Measure: Progression free survival (PFS) as assessed by using RANO-HGG criteria. After: Measure: Overall survival (OS).

Planned enrollment increased by 60 participants

Before: 450 participants (planned). After: 510 participants (planned).

Primary completion date changed

Before: Aug 2026. After: Jun 2028.

Check registry source